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Population-based surveillance for candidemia in
Australia from 2001 to 2004 identified 1,095 cases. Annual
overall and hospital-specific incidences were 1.81/100,000
and 0.21/1,000 separations (completed admissions),
respectively. Predisposing factors included malignancy
(32.1%), indwelling vascular catheters (72.6%), use of
antimicrobial agents (77%), and surgery (37.1%). Of 919
episodes, 81.5% were inpatient healthcare associated
(IHCA), 11.6% were outpatient healthcare associated
(OHCA), and 6.9% were community acquired (CA).
Concomitant illnesses and risk factors were similar in IHCA
and OHCA candidemia. IHCA candidemia was associated
with sepsis at diagnosis (p<0.001), death <30 days after
infection (p<0.001), and prolonged hospital admission
(p<0.001). Non–Candida albicans species (52.7%) caused
60.5% of cases acquired outside hospitals and 49.9% of
IHCA candidemia (p = 0.02). The 30-day death rate was
27.7% in those >65 years of age. Adult critical care stay,
sepsis syndrome, and corticosteroid therapy were associ-
ated with the greatest risk for death. Systematic epidemio-
logic studies that use standardized definitions for IHCA,
OHCA, and CA candidemia are indicated.
B
loodstream infections with Candida (candidemia)
account for 8% to 15% of hospital-acquired sepsis in
the United States (1,2). Death rates associated with can-
didemia are high (40%–70%) (3), with an estimated attrib-
utable death rate of 25% to 49% (4,5). Candidemia also
results in prolonged hospital stay and substantial health-
care costs (4,6).
Studies have shown that incidence and etiology of hos-
pital-acquired candidemia varied with geography, type of
hospital, population studied, and clinical practice (3,7–9).
Secular trends in the incidence of candidemia and etiologic
species of Candida differ between Europe and the United
States (10). Although candidemia is perceived as a hospital-
acquired infection, changes in medical practice to more fre-
quent use of home healthcare for many illnesses and
long-term indwelling vascular devices have increased the
number of susceptible patients in the community, potential-
ly increasing incidence and changing epidemiology.
Two population-based surveys in the United States
showed that 20% and 28% of cases were acquired outside
hospitals (7,11), compared with only 1.2% in Finland (12).
In a more recent study in Spain, 11% of episodes occurred
in outpatients (13). These studies are not directly compara-
ble because definitions of outpatient-acquired episodes
were different. In addition, within this group, little distinc-
tion was made between cases of healthcare-associated can-
didemia and community-acquired (CA) candidemia.
Aretrospective survey of candidemia in Australian hos-
pitals from 1995 to 1998 showed an increase in the annual
incidence of infection and a decrease in the proportion
caused by Candida albicans (14). The Australian
Candidemia Study Group was formed in 2001 to conduct
the first countrywide, population-based, active laboratory
surveillance for candidemia.
Methods
Study Design and Data Collection
Cases of candidemia were prospectively identified by
blood culture surveillance at 50 of 52 public and private
microbiology laboratories in Australia (population ≈20.1
million) from August 2001 to July 2004. One nonpartici-
pating laboratory provided services to a university
pediatric hospital where candidemia rarely occurred (A.
Daley, pers. comm.) and the other provided services to an
adult university hospital (36 cases identified; H. Sheorey,
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Adults, children, and neonates with <1 blood culture
yielding  Candida species were eligible for enrollment.
State or territory coordinators were responsible for case
identification. Information was collected on a standard
form regarding age, sex, patient location at time of can-
didemia diagnosis, healthcare setting, risk factors within
the preceding 30 days (including surgery, vascular access
devices [VADs], hyperalimentation, and use of antimicro-
bial and systemic antifungal agents), major concomitant
conditions (International Statistical Classification of
Diseases and Related Health Problems, 10th revision,
Australian modification) (15), portal of entry, clinical signs
of sepsis (16), complications of candidemia, results of
diagnostic studies, antifungal therapy, and clinical out-
come <30 days after diagnosis. All data were collected
prospectively, and forms were completed on days 5 and 30
after the date of the initial positive blood culture or at death
if it occurred earlier. Data were collected and analyzed at a
central site. Periodic audits of laboratory records ensured
that all cases of candidemia were reported. For the study
period, number of hospital beds and annual different day
patient separations (defined as completed admissions)
were obtained from 40 hospitals.
Definitions
A case was defined as incident isolation of Candida
species from blood during the study period. For patients
with >1 episode of candidemia, the second episode was
defined as a new case if it occurred >30 days after the pre-
vious episode. Atotal of >2 episodes fulfilling the case def-
inition and occurring in different patients who were
epidemiologically linked (e.g., with regard to risk factors,
location, and time) constituted a case cluster.
Episodes were classified as inpatient healthcare-associ-
ated (IHCA) if they occurred >48 hours after hospital
admission and had not clinically manifested on admission
(17). Cases occurring <48 hours after hospital admission
were considered outpatient-acquired. Among outpatient-
acquired candidemia, episodes associated with an
indwelling medical device, surgical procedure, or
chemotherapy-related neutropenia (<1×109 cells/L, adjust-
ed for children) were classified as outpatient healthcare
associated (OHCA), and CA infections were classified as
those occurring in patients with no healthcare-related risk
factors (17). Adult intensive care unit (ICU) acquisition
was when candidemia developed >48 hours after ICU
admission for nonneutropenic patients. Source of can-
didemia was considered VAD related if culture of the
device tip grew the same species isolated from blood.
Endocarditis was classified by modified Duke criteria (18).
Microbiologic Methods
All laboratories cultured blood specimens in BACTEC
(Becton Dickinson, Sparks, MD, USA) or BacT/Alert 3D
(bioMérieux, Marcy l’Etoile, France) automated systems.
Candida organisms were speciated by using standard phe-
notypic methods (19). Isolates were forwarded to a refer-
ence laboratory (Women’s and Children’s Hospital,
Adelaide) for susceptibility testing and species confirma-
tion by using conventional methods (20). Candida dublin-
iensis was distinguished from C. albicans by PCR
fingerprinting (21). Where identification was discordant,
species determination at the reference laboratory was used.
Statistical Analysis
Population and age-specific incidences were calculated
by using denominator data from the 2004 Australian cen-
sus (22) and hospital-specific incidences by using day of
separation denominator data from individual hospitals for
the study period. Overall incidences were expressed as
pooled mean rates calculated by aggregating numerators
and dividing by the sum of denominators from all sites.
Data were analyzed with SPSS version 10.0.7 (SPSS Inc.,
Chicago, IL, USA). Continuous variables were compared
with Student t test, and categorical variables were com-
pared with χ2 or Fisher exact tests. Incidence data from
university hospitals were pooled and compared with
pooled data from other hospital types with χ2 test. A p
value <0.05 was considered significant. Univariate analy-
ses were performed to identify risk factors associated with
overall illness. Candidate variables with a univariate
p<0.15, or previously published risk factors, were ana-
lyzed by multiple logistic regression. The same independ-
ent predictors of death were identified with forward,
backward, and stepwise variable selection methods.
Results
Incidence and Patient Demographics
Permission was denied to include 36 candidemia
episodes identified at the nonparticipating adult hospital.
Thus, the number of incident episodes was 1,095 (in 1,095
patients), with 337, 352, and 406 during the first, second,
and third years, respectively, of the study. Data on hospital
characteristics were available for 1,095 patients, demo-
graphic and clinical data for 1,005 (91.7%) episodes, and
outcome data for 857 (78.3%). Species were identified for
1,068 (97.5%) isolates.
The average population-based incidence of candidemia
was 1.81/100,000 (1.87/100,000 if inclusive of cases at the
nonparticipant hospital) per year (Table 1) and was highest
in infants (24.8/100,000) and persons ≥65 years of age
(13.7/100,000; Figure 1). Most cases (36.4%) occurred in
the most populous state, New South Wales, but incidence
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lation was similar by jurisdiction and similar to the nation-
al average (data not shown) except for the 2 least
populated areas, Northern Territory and Australian Capital
Territory, where the percentage of persons >65 years of age
was 4.4% and 9.3%, respectively, compared with the
national average of 13%.
The pooled mean annual hospital-specific incidence of
candidemia (data from 40 institutions) was 0.21/1,000 sep-
arations (range by jurisdiction 0.05–0.36) (Table 1). No
case clusters occurred. The estimated mean incidence in
university (n = 28) and university-affiliated hospitals (n =
9) was similar (0.22/1,000 separations, range by jurisdic-
tion 0.05–0.90) and greater than in private hospitals (n = 3,
0.1/1,000 separations, range by jurisdiction 0.04–0.16).
Neonates <1 month of age accounted for 33 (3.3%) of
1,005 cases, children 2 months to 14 years of age for 95
(9.5%) cases, adults 15–64 years of age for 527 (52.4%)
cases, and patients >65 years of age for 350 (34.8%) cases.
The median age was 56 years (range 0–98); 537 (53.4%)
episodes affected male patients.
Most cases occurred in medical wards (including can-
cer and hemopoietic stem cell transplant [HSCT] units;
390 [35.6%] of 1,095 cases), critical care units (273
[24.9%] cases), and surgical wards (193 [17.3%] cases).
Emergency (4.3%) and obstetrics and gynecology (0.5%)
services reported small percentages of episodes. Pediatric
cases occurred in pediatric critical care units (16 cases,
1.5%) and pediatric medical or surgical wards (24 cases,
2.2%). Neonatal infections occurred in premature or low
birthweight infants in neonatal critical care units (35 cases,
3.2%).
Concomitant Conditions, Risk Factors, 
and Healthcare Settings for Candidemia
Concomitant conditions and risk factor data were avail-
able for 1,005 episodes. Cancer was the most common
underlying condition (323 cases, 32.1%), with 164
episodes in solid tumor (50.8% cancers) cancer patients.
Of 159 cases diagnosed in patients with hematologic
malignancy, 91 occurred in patients with leukemia and 58
in those with lymphoma. Only 52 episodes occurred in
transplant recipients (17 allogeneic and HSCTs, 11 autolo-
gous HSCTs, and 24 solid organ transplants).
Gastrointestinal disorders (19%), chronic cardiovascular
disease (13.8%), and diabetes (13.6%) were common, but
pancreatitis was infrequent (2.5%), and coincident HIV
infection was rare (0.6%). Common iatrogenic risk factors
included indwelling VADs (72.6%), antimicrobial agents
(77%), major surgery (37.1%), and hyperalimentation
(33%, Table 2).
Of 919 episodes for which information on the health-
care setting was available, 749 (81.5%) were IHCA, 107
(11.6%, or 62.9% of outpatient-acquired cases) were
OHCA, and 63 (6.9%) were CA. The proportion of disease
acquired outside a hospital by jurisdiction ranged from
9.8% (4 of 41 cases in South Australia) to 50% (but only 1
of 2 cases in Northern Territory). Of the major states,
Western Australia reported the lowest percentage of
OHCA cases (1 [2.5%] of 40 episodes, Table 1).
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Figure 1. Annual age-specific incidence of candidemia, Australia,
2001–2004. Comparison of major concomitant conditions and risk fac-
tors according to healthcare setting is summarized in Table
2; >4 risk factors were evident in 195 (21.2%) episodes. A
total of 183 (20%) episodes were associated with use of an
adult ICU. Twenty-nine (93%) neonates received hyperal-
imentation compared with 35.4% of the adults. Systemic
antifungal agents were administered as prophylaxis in 67
(55.4%) of 121 instances; 48 (68.6%) of these prescrip-
tions were for hematology/HSCT patients.
Most (90%–100%) episodes associated with prematuri-
ty, organ transplantation, and burn or trauma were IHCA
(Table 2). Compared with all cases acquired outside a hos-
pital, patients with IHCAinfection were significantly more
likely to have had recent surgery (49% vs. 12.5%,
p<0.001), neutropenia (19.7% vs. 12.6%, p = 0.04),
indwelling VADs (90.1% vs. 48.4%, p<0.001), corticos-
teroid therapy (33% vs. 19%, p<0.001), or parenteral nutri-
tion (44.1% vs. 8.9%, p<0.001) or to have died within 30
days of infection (31.1% vs. 1.8%, p<0.001). These risk
factors, with the exception of surgery, were more common
in cases with OHCA candidemia than in those with CA
candidemia (Table 2).
Recent surgery and VADs, hyperalimentation, and
antimicrobial agents were more common in IHCApatients
than in OHCA patients (Table 2). Conversely, coincident
malignancy (44% vs. 34% episodes, p = 0.05) and cancer
chemotherapy (25.2% vs. 14.3%, p = 0.01) were associat-
ed with OHCA infection. OHCA patients also included
hemodialysis recipients and patients with diabetes. In CA
candidemia, common concomitant conditions included
intravenous drug use (IVDU, 23.8%), gastrointestinal dis-
orders (19%), diabetes (19%), behavioral disorders such as
chronic alcohol abuse (31.8%), and infectious diseases
(23.4%); 15 (50%) of 30 episodes in IVDU patients were
CA (Table 2). Differences in clinical manifestations were
identified in the 3 groups. Patients with IHCA candidemia
were more likely to have sepsis, die within 30 days, remain
in hospital longer, and have concomitant healthcare-asso-
ciated bacteremia (Table 2). Of 34 patients with Candida
endocarditis (13 definite and 21 possible), 7 were OHCA
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IHCA candidemia (Table 2).
Candida Species
Species of Candida was correctly identified in 96.7%
instances in which identity was established. C. albicans
was the most common species (505 [47.3%] of 1,068
episodes) followed by C.  parapsilosis (19.9%) and C.
glabrata (15.4%). C. tropicalis, C. krusei, and C. dublin-
iensis were identified in 5.1%, 4.3%, and 1.9%, respective-
ly, of the patients. The remaining 42 (4.0%) episodes were
caused by C. guilliermondi (n = 11), C. lusitaniae (n = 7),
C. kefyr (n = 5), C. famata (n = 3), C. rugosa (n = 3), and
C. pelliculosa (n = 3). There were 24 (2.2%) episodes of
polycandidal infection and an increase in the proportion of
C. glabrata candidemia from 10.1% episodes the first year
to 19.5% episodes in the third year of the study (p = 0.02,
data not shown).
C. albicans was the predominant species in Tasmania
(60%), Australian Capital Territory (77%), and Western
Australia (54.1%). However, this species caused only
37.8% of episodes in South Australia, whereas 31.1% were
caused by C.  parapsilosis (7.7%–21.9% of cases else-
where). C. krusei and C. dubliniensis candidemia were rare
in the least populous jurisdictions where complex proce-
dures such as HSCT are not performed. Age distribution,
including proportion of neonates and children in the popu-
lation, was comparable for all jurisdictions (data not
shown).
Species other than C. albicans were isolated more often
from patients with candidemia acquired outside a hospital
(60.5% vs. 49.9% for IHCA candidemia, p = 0.02). C.
parapsilosis was recovered from 30.9% of these episodes
(compared with 16.7% of IHCA episodes, p<0.001),
although  C.  krusei and  C. dubliniensis candidemia was
rare. Relative proportions of infections caused by C. albi-
cans and non–C. albicans species in cases of OHCA can-
didemia and CA candidemia were similar.
In neonates and children, C. parapsilosis accounted for
a similar proportion of episodes as did C. albicans; other
species were rare. C.  albicans was the most common
causative pathogen in adults (48.6% of cases) and C.
glabrata, C. parapsilosis, and other Candida species were
approximately equally distributed (Figure 2). Eighty
(53.3%) of 150 episodes in patients >65 years of age were
caused by C. glabrata.
C. albicans was the most common pathogen in ICUs
(61.7% of episodes) and surgical (54.4% of episodes)
patients but caused only 32% of episodes in hematology
patients, who had the highest proportion (24 [66.7%] of 36
episodes) of infection with C.  krusei.  C.  parapsilosis
accounted for 42.9% of episodes in neonatal ICUs and for
42.4% of cases in patients without hematologic cancer. C.
glabrata was present in all patient groups. Twelve (63.2%)
of 19 episodes of C. dubliniensis candidemia were in sur-
gical and nonhematology patients.
Outcome
The all-cause 30-day death rate was 27.7% (236 of 853
episodes) and similar in all age groups. Clinician-reported
attributable deaths were lower (93 episodes, 10.9%). The
death rate was higher in IHCA episodes than in either
OHCA or CA episodes (Table 2). Univariate analysis
showed that numerous variables were associated with
increased death (Table 3). Multiple logistic regression
analysis of 16 variables showed that an age >65 years, ICU
stay, sepsis at diagnosis, and corticosteroid therapy
(p<0.001, Table 4) were associated with the greatest risk
for death. C. glabrata infection was also an independent
predictor of death. Treatment with an antifungal agent (752
[85.8%] of 876 episodes) was independently associated
with lower odds of death but removal of a VAD (76.4% of
878 instances where VADs were in situ at diagnosis) was
not (Table 4). However, in the subset of VAD-related can-
didemia episodes (n = 409), removal of the VAD (n = 339)
was associated with a better outcome (odds ratio 0.48, 95%
confidence interval 0.26–0.88, p = 0.02).
Discussion
This study provides the first contemporary, comprehen-
sive, population-based description of candidemia across a
continent. Overall disease incidence (1.81/100,000) was
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Figure 2. Distribution of causative pathogen according to patient
age for 978 Candida species, Australia, 2001–2004.similar to that in Europe (1.4–4.9/100,000) (12,23) but dif-
ferent from that in the United States (6–10/100,000)
(7,11,24). Most US and European surveys were not popu-
lation-based and those that were included patients from
specific areas (11,13,24). Age distribution of the popula-
tion affected estimates, as shown by higher incidence
among young and elderly people in Australia. Geographic
variations in incidence were observed across Australia.
However, this finding was unlikely to be caused by differ-
ences in age distribution because this distribution was sim-
ilar in all states. Although the proportion of elderly persons
was lower in Northern Territory and Australian Capital
Territory, only 19 of 1,095 cases were in these jurisdic-
tions. 
As expected, mean incidence of candidemia was high-
er in university hospitals and university-affiliated hospi-
tals, which have a higher proportion of patients at risk for
candidemia (0.22/1,000 separations each) than private hos-
pitals (0.1/1,000 separations). Since similar clinical man-
agement practices are used throughout Australia,
jurisdictional differences are likely caused by different
exposures to risk factors for infection. The highest inci-
dences were observed in jurisdictions with organ trans-
plantation, burn, and critical care centers.
Concomitant conditions and risk factors associated
with candidemia were similar to those previously
described (11,25), but pancreatitis (26) and HIV infection
(8%–10% of cases in the United States) (7,11) were rare,
and only 20% of episodes were associated with an ICU
(33%–40% elsewhere) (7,13,25). We observed approxi-
mately equal numbers of cases in hematologic and solid
tumor cancer patients. However, in previous studies, solid
tumor patients were more common (6,11,25). Whether the
prevalence of candidemia is increasing in the setting of
chemotherapy for hematologic malignancy, despite use of
antifungal prophylaxis in selected patients, is the subject of
ongoing study.
Australian hospital statistics showed a 4% increase in
community-based healthcare from 2000 through 2003
(27). Using population-based surveillance, we identified
≈20% of candidemia episodes that would not have been
captured by nosocomial surveillance. This proportion is
higher than in Europe (6%–10%) (12,13), but lower than in
the United States (20%–28%) (7,11). However, these pro-
portions are not directly comparable since previous studies
have used different criteria to define outpatient-acquired
episodes. Although most studies required blood cultures to
be positive <48 hours of patient admission (1,13), others
have used ≤72 hours (28) or ≤24 hours (7,11). If one
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suggest that 48 hours is appropriate. Furthermore, previous
studies have not distinguished between CA and OHCA
infections (7,11,13,28).
Using a national standard classification for bloodstream
infections (17), we identified differences and similarities
between IHCA candidemia and candidemia acquired out-
side a hospital and between OHCA and CA infections.
Most (>60%) outpatient cases were healthcare associated.
These cases resembled IHCA candidemia because cancer
and other chronic diseases were common concomitant
conditions and established risk factors were often present,
although less frequently, than in IHCA infection; they dif-
fered from CA candidemia in instances in which IVDU
was a risk factor. Thus, emergence of candidemia outside
the hospital setting is likely due to the shift in persons with
iatrogenic risk factors, such as chemotherapy and intra-
venous antimicrobial drug therapy, increasing manage-
ment of more serious conditions outside the hospital, and
implementation of early hospital discharge. Home-based
therapies have been implicated in at least 1 outbreak of
outpatient candidemia (29).
Compared with IHCA infection, the 30-day death rate
and duration of hospital stay were lower in OHCA cases.
Candidemia may have been more severe in the IHCA
group because sepsis was initially identified in a higher
proportion of these patients than in OHCA patients and
was an independent predictor of death. Concomitant bac-
teremia was more common in IHCA patients. However,
since no control group was studied, the difference may be
explained by other characteristics of hospitalized patients
compared with outpatients. Clinical outcomes of OHCA
and CA candidemia were similar, although sepsis was
present at diagnosis in a higher proportion of OHCA
patients. Candidemia should be included in the differential
diagnosis of patients with appropriate risk factors and sep-
sis who are admitted to emergency departments or in other
healthcare settings.
Species distribution varied by jurisdiction, healthcare
setting, age, and hospital service. In South Australia, C.
albicans was less common and C. parapsilosis was more
prevalent. This finding was not explained by differences in
age distribution or proportions of IHCA and OHCA infec-
tions between jurisdictions. Overall, C. parapsilosis can-
didemia was more prevalent in outpatients, many of whom
had VADs in situ, and in neonates, which is consistent with
previous studies (7,11). Given the reduced susceptibility of
C. glabrata to azole drugs (30), our observations that C.
glabrata candidemia occurs more often in patients without
hematologic malignancy and that these infections
increased during the study provide useful data. In other
studies, C. glabrata was more common in older persons
(31) and patients with hematologic cancer (24).
The high overall death rate, albeit lower than reported
elsewhere (35%–44%) (7,12,13), is another reminder of
the role of candidemia in healthcare settings. The highest
case-fatality rate was observed in the most vulnerable
patients (elderly, ICU patients, and those who recently had
medical interventions). Sepsis syndrome and failure to
institute treatment with antifungal drugs (the latter
occurred mainly in preterminal hematology patients) were
independent predictors of death. Although removal of
VADs did not independently protect against death, data
from univariate analysis (Table 3) support current recom-
mendations to remove VADs when candidemia is detected
(32).
In conclusion, although candidemia is primarily a
healthcare-associated entity in patients with established
risk factors, many of these patients are observed in the out-
patient setting. OHCAinfections have characteristics inter-
mediate between those of IHCA and CA infections. We
propose that cases of candidemia be categorized as IHCA,
OHCA, and CA, with the term CA reserved for those
episodes occurring <48 hours of hospital admission and
that do not meet criteria for healthcare-associated infec-
tions. Further study of secular trends and characteristics of
candidemia acquired outside hospitals with standardized
definitions is warranted. Surveillance is needed to track
trends of this serious infection and provide guidelines for
antifungal prophylaxis, treatment, and infection control
strategies.
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